Provided by Tiger Trade Technology Pte. Ltd.

Lunai Bioworks

1.30
-0.0800-5.80%
Post-market: 1.300.00000.00%16:10 EDT
Volume:124.88K
Turnover:168.79K
Market Cap:5.89M
PE:-0.02
High:1.46
Open:1.44
Low:1.23
Close:1.38
52wk High:13.28
52wk Low:1.21
Shares:4.53M
Float Shares:2.87M
Volume Ratio:2.36
T/O Rate:4.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-61.5200
EPS(LYR):-86.2743
ROE:-325.46%
ROA:-9.65%
PB:-0.62
PE(LYR):-0.02

Loading ...

Tianci International (CIIT) Stock Jumps Nearly 15% After Hours: Here's What Is Going On

Benzinga Earnings
·
Jun 17

Lunai Bioworks - Regains Nasdaq Compliance With Minimum $1 Bid Price Rule - SEC Filing

THOMSON REUTERS
·
Jun 17

Lunai Bioworks regains Nasdaq $1 minimum bid price compliance, enters one-year monitoring period

Reuters
·
Jun 17

Lunai Bioworks unit BioSymetrics enters neurology target discovery collaboration with BrainStorm Therapeutics

Reuters
·
May 28

Lunai Bioworks and Brainstorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration

THOMSON REUTERS
·
May 28

Lunai Bioworks Inc - Federal Judge Grants Lunai Bioworks Expedited Discovery to Identify "Naked" Short Sellers

THOMSON REUTERS
·
May 22

Lunai Bioworks wins expedited discovery to identify alleged naked short sellers

Reuters
·
May 22

Lunai Bioworks Inc. trading halted, news pending

TIPRANKS
·
May 22

Lunai Bioworks to Execute 1-for-8 Reverse Stock Split Effective May 22 to Regain Nasdaq Compliance

Deep News
·
May 21

Lunai Bioworks announces reverse stock split

TIPRANKS
·
May 20

Lunai Bioworks effects 1-for-8 reverse stock split May 22

Reuters
·
May 20

Lunai Bioworks, Inc. Announces Reverse Stock Split

THOMSON REUTERS
·
May 20

Lunai Bioworks Inc. - Common Stock Q3 EPS $(0.10), Sales $20.942K

Benzinga Earnings
·
May 16

Lunai Bioworks Q3 FY26 net loss widens to $2.57 million; revenue $20,942

Reuters
·
May 16

Lunai Bioworks Inc - Approves Reverse Stock Split at Ratio of 1-for-3 to 1-for-30 - SEC Filing

THOMSON REUTERS
·
May 14

Lunai Bioworks shareholders approved reverse stock split amendment at special meeting

Reuters
·
May 14

Lunai Bioworks amends 8-K to disclose Nasdaq MVLS noncompliance delisting basis

Reuters
·
May 12

Lunai Bioworks completes $20 million preferred stock issuance in private placement

Reuters
·
May 04

Press Release: Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

Dow Jones
·
May 04

Lunai Bioworks completes Neurobridge IP Holdings merger, issues $20 million preferred stock

Reuters
·
May 02